title: Pharmaceutical Approval Update.
abstract: Idarucizumab (Praxbind) to reverse the anticoagulant effects of dabigatran (Pradaxa); aripiprazole lauroxil (Aristada) for the treatment of schizophrenia; and insulin degludec injection (Tresiba) for diabetes.
authors.forename: Chris
authors.initials: C
authors.lastname: Fellner